812(1) obtain the simulated paths of discounted future exposure from the exposure models used by the firm for calculating CVA under the firm’s applicable accounting framework, adjusted as necessary to meet the requirements of this Chapter; and
814(2) use the same model calibration process (with the exception of the margin period of risk), market and transaction data as it uses for calculating CVA under the firm’s applicable accounting framework.
835A firm must ensure that its calculation of regulatory CVA recognises netting sets in the same manner in which the firm calculates CVA under the firm’s applicable accounting framework.
845(1) its exposure models used for calculating regulatory CVA are part of a CVA risk management framework that includes the identification, measurement, management, approval and internal reporting of CVA risk;
847(2) its senior management is actively involved in the risk control process and must regard CVA risk control as an essential aspect of the business to which sufficient resources are devoted;
849(3) it has a process for ensuring compliance with a documented set of internal policies, controls and procedures concerning the operation of the exposure system it uses for calculating CVA under the firm’s applicable accounting framework;
858(5) its documentation of the process for initial and ongoing validation of its exposure models:
859(a) is detailed enough to enable a third party to understand how the models operate, their limitations, and their key assumptions, and to recreate the analysis;
861(b) sets out the minimum frequency with which ongoing validation will be conducted as well as other circumstances under which additional validation will be conducted; and
863(c) describes how the validation is conducted with respect to data flows and portfolios, what analyses are used and how representative counterparty portfolios are constructed;
865(6) the pricing models used to calculate exposure for a given path of risk factors must:
866(a) be tested against appropriate independent benchmarks for a wide range of market states as part of the initial and ongoing model validation process; and
870(7) its internal audit function carries out an independent review of the overall CVA risk management process on a regular basis, covering both the activities of the CVA desk and the independent risk control unit;
872(8) it defines criteria against which to assess the exposure models and their inputs, and has a written policy describing the process to assess performance of the exposure models and remedy unacceptable performance;
882(13) it subjects the transmission of transaction terms and specifications data to the exposure model to internal audit and formal reconciliation processes are in place between the exposure model and source data systems to verify on an ongoing basis that transaction terms and specifications are reflected in the exposure model appropriately;
893(15) it sets internal policies to identify suitable proxies where its exposure models rely on proxy market data and it can demonstrate empirically on an ongoing basis that the proxy provides a conservative representation of the underlying risk under adverse market conditions.